UROTENSIN II
============

The peptide Urotensin II (UII) was first identified in the teleost fish *Gillichthys mirabilis* ([@B110]). Homologs of this peptide were subsequently found in mammals and humans ([@B110]; [@B25]; [@B2]; [@B27]). Although the amino acid sequence of these homologs changes depending on the species, a cyclic sequence of six amino acids is conserved (Cys-Phe-Trp-Lys-Tyr-Cys). It is believed that this sequence is responsible for the biological activity of the peptide ([@B24]). UII acts as a vasoactive peptide by binding to the G protein coupled receptor GPR14, better known as UT ([@B2]; [@B89]). A recent study has shown that UII vasoconstrictive effects are mediated by calcium influx via STIM1 and Orai-1 ([@B32]). Human UII (hUII) and its receptor have been found in cardiac and vascular tissues, spinal cord, central nervous system, kidney, liver, and pancreas ([@B91]; [@B94]). UII is also present in the blood plasma in picomolar concentrations ([@B94]). However, it tends to act mainly in an autocrine and paracrine fashion rather than as a hormone ([@B160]). Even though the relation between UII and its receptor was made in 1999, the physiological and pathological roles of UII are only beginning to be unraveled. In a healthy state, the binding of UII with UT is known to play an important role in the control of vascular tone, blood pressure, and insulin release ([@B35]; [@B36]; [@B90]). UII has been identified as the most potent vasoactive peptide known to date, being more potent vasoconstrictor than endothelin-1 and angiotensin-II ([@B2]; [@B35]; [@B91]). UII also controls the function of vascular smooth-muscle cells (VSMCs) through the release of endothelial-cell-derived vasodilators such as nitric oxide ([@B50]; [@B49]; [@B135]). The role of UII in pathological states is still debated. Many studies have shown increased levels of UII and its receptor in diverse cardiovascular and metabolic diseases such as type 2 diabetes mellitus, renal dysfunction, atherosclerosis, systematic and essential hypertension, obesity, congestive heart failure, myocardial infarction, cardiac fibrosis, hypertrophy, and remodeling (Reviewed in [@B64]; [@B117]; [@B60]). The elevated levels of UII in disease states suggest that UII is expressed either as a protective response to pathologies or as a pathological agent. Some studies claim that temporary elevation of UII levels may lower cardiovascular disease risk factors in end-stage renal disease ([@B93]; [@B167]), myocardial infarction ([@B4]) and restore endothelial function ([@B168]). On the other hand, other studies have demonstrated that UII acts as a pathological agent inducing cardiac hypertrophy in synergy with angiotensin II by phosphorylation of the Akt kinase ([@B19]; [@B59], [@B60]).

METABOLIC SYNDROME
==================

As mentioned above, the metabolic syndrome (MetS) consists of a set of risk factors, such as obesity, hyperlipidemia, hypertension, hyperglycemia, and insulin resistance (IR), leading to the development of type 2 diabetes, cardiovascular diseases, non-alcoholic fatty liver disease, and renal impairment ([@B56]; [@B22]). The relation between these risk factors and complications seems to be mostly attributed to IR ([@B38]), which is why the syndrome was first defined as an IR syndrome ([@B115]). Since then, the National Cholesterol Education Program (NCEP)-Adult Treatment Panel III, the World Health Organization (WHO) and the International Diabetes Federation (IDF) set up some criteria for the clinical definition of MetS.

A recent study using data from the 2003--2006 National Health and Nutrition Examination Survey and the NCEP/IDF MetS criteria, revealed that the prevalence of MetS was 34.3% among all adults in the US ([@B47]). However, high prevalence of MetS is not only restricted to the Western world. MetS seems to be highly prevalent in sub-Saharan Africa, Middle-East, South America, and South Asian Countries ([@B98]). Central obesity is considered the main precursor to MetS ([@B16]). According to the WHO, the global obese population increased from 200 million in 1995 to 300 million in 2000. The WHO has also determined that the obesity epidemic is also spreading in developing countries with over 115 million people suffering from obesity-related illnesses ([@B98]; [@B158]). [@B111] have also reported increasing obesity prevalence in the United States, Latin America, Europe, and Asia, which confirms the worldwide epidemic proportions of obesity and overweight. In addition, the Aerobic Center Longitudinal Study, which included 33,230 cancer-free men followed for 14 years, showed 56% enhanced risk of cancer mortality for men affected by MetS ([@B73]). The direct implication of the syndrome in CVD, type 2 diabetes, non-alcoholic fatty liver, and cancer, as well as an increasing prevalence of obesity and decreased physical inactivity in Western societies makes the MetS a major health preoccupation ([@B100])

Recent researches have shown that UII has an impact on the risk factors as well as the overall pathogenesis of the MetS ([@B105]). A study using the American Heart Association/National Heart, Lung, and Blood Institute criteria for MetS revealed that MetS patients show higher plasma levels of UII ([@B58]). Our group also demonstrated an increase in UII plasma levels in mice when all risk factors of MetS are present ([@B161]). Moreover, we recently found that UII gene deletion in mice (UIIKO) significantly decreased body mass, visceral fat, blood pressure, and increased insulin and glucose tolerance when compared to wild-type mice ([@B161]). Even though there is a clear association between MetS and UII, it is still unclear whether the peptide plays a role in the initiation of the disease, or if the elevated plasma levels of UII are a result of the syndrome. This review aims to give a closer look at the implication of UII in the risk factors and pathways involved in the development of the MetS.

INSULIN RESISTANCE (IR)
=======================

Insulin plays a major role in glucose and lipid metabolism such as adipose tissue triglyceride lipolysis, lipoprotein lipase activity, muscle and adipose tissue glucose absorption, muscle and liver glycogen synthesis, and endogenous glucose production ([@B26]). When cells react poorly to an insulin stimulus, they are defined as IR. The latter is known to be the link between the individual components of MetS ([@B38]). For instance, it seems that IR correlates positively with atherosclerosis ([@B43]) and coronary artery disease (CAD; [@B78]), and also an indirect cause of hyperinsulinemia ([@B116]), dyslipidemia, hyperglycemia, and hypertension ([@B132]) through an increase in free fatty acid (FFA) synthesis in adipose tissue ([@B11]) and a chronic inflammatory response ([@B43]).

The IR Atherosclerosis Study (IRAS) and the Atherosclerosis Risk in Communities Study showed that insulin sensitivity (measured with an intravenous glucose tolerance test) correlates negatively with intimal-medial thickness of the carotid artery ([@B71]). Subsequent studies also found a significant correlation between carotid intimal-media thickening and IR and hyperinsulinemia ([@B51]; [@B163]). Intimal-media thickness has been shown to be a significant predictor of myocardial infarction and coronary death ([@B67]). As a result, IR is a major risk factor in developing cardiovascular complications. Indeed, IR has been associated with increased plasma levels of plasminogen activator inhibitor 1 (PAI-1; [@B78]). Increased levels of PAI-1 are known to impair fibrinolysis, which leads to progression of coronary atherosclerosis in glucose intolerant patients ([@B7]) and increased risk of myocardial reinfarction within 3 years in less than 45-year-old men ([@B61], [@B62]; [@B52]; [@B78]) as well as increased risk of CAD ([@B78]). UII is known to increase expression of PAI-1 in vascular SMC ([@B31]), hence UII may contribute to atherosclerosis through PAI-1 inhibition of fibrinolysis.

Free fatty acids play an important role in MetS by having direct effects on dyslipidemia, hypertension ([@B40]), IR ([@B10]), and pancreatic β-cell dysfunction ([@B121]; [@B147]; [@B96]; [@B11]). Impaired insulin action in adipose tissue tends to increase FFAs concentrations in the plasma by reducing the insulin inhibition of adipose tissue triglyceride lipolysis ([@B114]; [@B113]; [@B80]; [@B26]). On the other hand, FFAs induce IR in skeletal muscles ([@B30]) and liver by inhibiting insulin suppression of glycogenolysis ([@B12]), which results in a vicious cycle increasing IR, FFA levels, and promotion of hyperglycemia. Furthermore, higher plasma glucose and FFA levels tend to increase insulin secretion in the pancreas ([@B11]), thus leading to hyperinsulinemia. Such high plasma insulin levels promote hypertension ([@B156]; [@B116]), which is another risk factor of MetS. An increase in FFA levels also predicts development of type 2 diabetes ([@B107]; [@B20]). In the liver, higher FFA levels increase low density lipoprotein (LDL) and triglyceride production, while lowering high density lipoprotein (HDL) production ([@B15]; [@B99]).

The direct effects of UII on lipid mobilization and FFA release are somewhat contradictory. In the coho salmon, administration of UII stimulated the activity of triacylglycerol lipase and the release of FFAs in the liver ([@B126]; [@B127]). On the contrary, UII injection in dogfish showed no significant increase in FFA release or plasma triglyceride concentrations ([@B23]). We recently found that UII gene deletion in mice fed high fat diet significantly reduced serum levels of FFAs in comparison with wild-type ([@B161]). In light of our own findings and those of others linking UII to IR and glucose metabolism ([@B129], [@B128]; [@B106]; [@B161]), we suggest that UII may mediate lipid mobilization and FFA indirectly through IR. However, the direct influence of UII in lipid metabolism still requires further research.

The role of UII in the MetS seems to be closely related to insulin activity and the overall glucose metabolism in the pancreas (**Figure [1](#F1){ref-type="fig"}**). In fact, UII and UT are both expressed in rat pancreatic islets, where their interaction seems to inhibit glucose-mediated insulin release ([@B129], [@B128]). Also, when high concentrations of UII are administrated to the rat pancreas, glucose and arginine induced insulin response are blocked ([@B129], [@B128]). Some UII and UT gene haplotypes are known to be associated with IR ([@B106]), impaired glucose tolerance ([@B106]), β-cell pancreatic function, and type 2 diabetes ([@B137]; [@B169]; [@B157]; [@B139]; [@B142]; [@B120]). UII upregulation in plasma and skeletal muscle in type 2 diabetes mellitus is coherent with this association ([@B143]; [@B150]). In addition, UII increases glucose-6-phosphatase activity in salmon liver, which tends to reduce glycogen content and increase glucose levels, leading to hyperglycemia. Our recent study has demonstrated that UII gene knockout in mice reduced serum glucose and insulin, and increased glucose and insulin tolerance in comparison with wild-type mice ([@B161]).

![**Summary of the role of Urotensin II (UII) on insulin activity and glucose metabolism associated with the metabolic syndrome**. UII expressed in the pancreas acts directly to impair glucose tolerance, reduce glucose-mediated insulin release, impair pancreatic β-cell function, and block insulin response resulting in IR and increased risk of type 2 diabetes and cardiovascular diseases.](fendo-03-00165-g001){#F1}

INFLAMMATORY RESPONSE IN THE MetS
=================================

It is well known that IR and MetS are both associated with an inflammatory response ([@B138]). The relationship between IR and inflammation seems to be bidirectional; IR promotes an inflammatory response and vice versa ([@B43]), resulting in a vicious circle increasing risk of MetS incidence. An acute-phase inflammatory response is not only linked with IR ([@B42]; [@B45]; [@B55]; [@B85]), but also with type 2 diabetes ([@B97]; [@B3]; [@B45]; [@B85]), obesity ([@B83]; [@B85]), and the overall MetS ([@B18]; [@B29]). The activity of inflammatory markers such as C-reactive protein, tumor necrosis factor-alpha (TNF-α), Interleukin-18 (IL-18) and PAI-1 increases as the presence of MetS risk factors increase ([@B26]).

Tumor necrosis factor-alpha prevents the action of insulin in cultured cells and in animal models ([@B70], [@B68], [@B69]) by inducing serine phosphorylation of the insulin receptor substrate-1, which reduces the tyrosine kinase activity of the insulin receptor ([@B69]), resulting in IR. Furthermore, TNF-α stimulates the production of endothelin-1 ([@B79]) and angiotensin ([@B14]) *in vitro*, which are directly involved in vasoconstriction and thus may lead to increased hypertension. Indeed, there is a positive correlation between TNF-α, systolic blood pressure, and IR ([@B34]). TNF-α also stimulates VLDL production ([@B57]) and decreases HDL cholesterol ([@B77]). Dyslipidemia in mice is significantly related to increased TNF-α levels ([@B46]).

Elevated levels of the inflammatory cytokine IL-6 are associated with obesity, IR ([@B48]; [@B5]; [@B42]; [@B81]; [@B6]), and type 2 diabetes ([@B112]; [@B149]). IL-6 also plays a role in the pathology of dyslipidemia by decreasing LPL activity in adipocytes ([@B53]) which increases hepatic triglyceride levels ([@B103]). In man, IL-6 correlates with increased FFA ([@B136]), fasting triglycerides, and VLDL ([@B41]), and decreased HDL cholesterol ([@B172]). This cytokine may also have an impact on hypertension by stimulating the sympathetic and central nervous system ([@B9]; [@B109]), and angiotensin expression ([@B140]).

The central role of the inflammatory response in MetS is also related to UII and UT expression (**Figure [2](#F2){ref-type="fig"}**). Inflammatory cells including lymphocytes, macrophages, monocytes, and foam cells express UII and UT mRNA ([@B13]). Lymphocytes are by far the largest producers of UII, whereas monocytes and macrophages produce the highest levels of UT. Moreover, inflammatory markers such as TNF-α, lipopolysaccharide, and interferon-γ are all known to induce UT expression *in vitro* ([@B125]). These findings suggest that an inflammatory response to MetS and its components may increase UII levels by increasing inflammatory cells production of the peptide. On the other hand, UII is known to contribute to the inflammatory response by inducing the release of inflammatory cytokines like IL-6 in cardiomyocytes ([@B122]; [@B146]; [@B76]; [@B119]). UII mediates aortic inflammation by stimulating the release of leukotriene C (LTC~4~), a lipid inflammatory mediator, from aortic adventitial fibroblasts through 5-lipoxygenase pathway ([@B33]). LTC~4~ plays a key role in the pathogenesis of atherosclerosis as a chemoattractant and activator for monocytes in the vascular endothelium. It is also known to initiate contraction of smooth muscle cells in the adjacent medial tissues of the vasculature ([@B33]). In addition, we have recently shown that UII gene deletion in mice fed a high fat diet reduces the serum levels of inflammatory cytokines including monocyte chemoattractant protein-1, monokine induced by γ-interferon, and keratinocyte chemoattractant when compared to wild-type mice ([@B161]).

![**Summary of the role of Urotensin II (UII) on the inflammatory response associated with the metabolic syndrome**. Inflammatory cytokines increase UII and UT expression and vice-versa, resulting in a positive feedback. The ensuing chronic inflammation is directly involved in the development of obesity, insulin resistance, dyslipidemia, hypertension, and atherosclerosis.](fendo-03-00165-g002){#F2}

UII, HYPERTENSION, AND CARDIOVASCULAR DISEASES
==============================================

The MetS is identified as a clustering of risk factors that perpetuate cardiovascular diseases. Since UII has been shown to play a role in the pathogenesis of atherosclerosis ([@B92]; [@B65]; [@B108]), congestive heart failure ([@B64]), myocardial ischemia ([@B164]; [@B166]), ventricular hypertrophy, and fibrosis ([@B122]; [@B146]; [@B76]; [@B119]), it is therefore reasonable to suggest that induction of UII in the MetS may contribute to the cardiovascular abnormalities associated with this syndrome.

Atherosclerosis is the main cause of morbidity and mortality in cardiovascular diseases and cause of death in the Western world ([@B86]). Atherosclerosis is known to induce UT and UII overexpression in mice aortic tissues ([@B37]; [@B13]; [@B151]; [@B86]). In mice overexpressing UT receptor (UT^+^), aortic atherosclerosis lesion formation is significantly increased ([@B108]), whereas lesion formation is decreased in UIIKO mice with an atherosclerotic background (APOE; [@B161]). UII is known to promote vascular remodeling by mediating VSMC proliferation and migration inside the intima, a process directly involved in atherogenesis ([@B124]; [@B152],[@B153]; [@B141]; [@B1]; [@B72]). It has been suggested that vascular endothelial growth factor (VEGF), a major angiogenic protein, could be responsible for UII-mediated vascular remodeling. Even though UII does not affect VEGF expression in human endothelium ([@B1]), recent evidence has shown that UII induces secretion of VEGF in the adventitia in synergy with angiotensin II ([@B131]). VEGF stimulates proliferation of endothelial and smooth muscles cells while also stimulating proliferation and migration of adventitial fibroblasts in the intima ([@B123]; [@B134]; [@B165]). In addition, UII contributes to the inflammatory response in atherosclerosis by acting as a chemoattractant for monocytes ([@B125]) and increasing IL-6 expression in cardiomyocytes ([@B122]; [@B146]; [@B76]; [@B119]). UII interacts with UT receptors on the surface of macrophages to promote expression of ACAT-1 ([@B154]). ACAT-1 is known to accelerate foam cells formation, which has a major impact on atherosclerotic lesion development ([@B154]). Another main effect of UII on atherosclerosis is the increased expression of NADPH oxidase, which is a main source of reactive oxygen species (ROS; [@B31]; [@B145]). ROS are central in the early initiation of atherosclerosis by converting LDL into oxidized-LDL ([@B31]). NADPH oxidase-derived superoxide inactivates nitric oxide, resulting in impaired endothelial dependant vasodilatation ([@B171]) and hypertension ([@B84]).

Urotensin II also contributes to essential ([@B94]) and secondary ([@B66]) hypertension by inducing vascular remodeling. Increased blood pressure in cats ([@B8]), rats ([@B88]), and sheep ([@B155]) with UII administration is coherent with these findings. In humans, plasma UII correlates positively with systolic blood pressure, independently of an atherosclerotic background ([@B21]). Indeed, the UII gene (UTS2) is associated with essential hypertension ([@B159]) and myocardial infarction ([@B102]; [@B104]). In a chronic heart failure or essential hypertension state, UII loses its dilatory function ([@B87]; [@B130]).

UII, OBESITY, AND HYPERLIPIDEMIA
================================

Obesity seems to be a main cause of IR in both men and women ([@B17]; [@B26]; [@B133]). Moreover, it seems that physical activity and a diet rich in monounsaturated or hydrogenated fat leads to an impairment of insulin sensitivity ([@B95]; [@B148]; [@B63]). Obesity is also known as a chronic inflammatory state; it induces release of proinflammatory cytokines and adipokines ([@B162]; [@B44]; [@B39]; [@B144]). As a result, the pathologic role of inflammation in IR and MetS may be enhanced by obesity. However, some suggest that obesity may be, on the opposite, an outcome of inflammation ([@B28]). Obesity may contribute to increase local IR in the adipocytes as well as in other tissue such as the liver and skeletal muscles ([@B26]; [@B54]).

Plasma UII correlates positively with body weight in humans independently of atherosclerotic background ([@B21]). Adipokines (dipeptidyl peptidase-4, endocan, insulin-like growth factor-binding proteins), known to play a role in diabetes mellitus and obesity ([@B74]; [@B101]; [@B118]) were reduced in UII/ApoE double knockout mice in comparison with ApoEKO ([@B161]). Reduction of body mass, visceral fat, visceral adipocytes diameter, serum LDL, triglycerides, as well as increase in HDL is also observed with UII gene deletion in mice ([@B161]; **Figure [3](#F3){ref-type="fig"}**). A reduction in hepatic cholesterol esterification is also observed in UIIKO mice ([@B82]). These results are attributed to a reduction in cholesterol and apolipoprotein B production by hepatocytes ([@B82]). Furthermore, [@B75] found that the UII gene (UTS2) regulates fat accumulation in humans.

![**Hematoxylin and eosin staining of visceral adipose tissue sections in wild-type mice (A) and UIIKO mice (B)**. Adipocytes of UIIKO mice appear smaller than wild-type mice.](fendo-03-00165-g003){#F3}

CONCLUSION
==========

The mechanism that links the various components of MetS relies primarily on IR and inflammation ([@B138]; [@B38]). The ability of UII to modulate both of these factors suggests an important role for the peptide in the pathogenesis of the MetS. Other risk factors mediated by UII, such as obesity, may tend to initiate the positive feedback cycle, which contributes to the development of MetS. In fact, genetic manipulation or the use of UT receptor antagonists seems to have a positive effect on every risk factor of the MetS ([@B161]). However, it is still unclear whether UII is important in the initiation or only in the progression and further complications of the disease. The biological activities of UII, and the recent reports of increased serum levels of UII in patients with the MetS suggest that pharmacological manipulation of the UII pathway as a possible future treatment of the syndrome.
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